Federated Hermes’s Acceleron Pharma XLRN Stock Holding History

Federated Hermes’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-13,650	Closed	-$1.85M	–	2393
2021 Q1	$1.85M	Sell	13,650 -3,785	-22%	-$489K	﹤0.01%	1136
2020 Q4	$2.23M	Sell	17,435 -25,835	-60%	-$3.03M	﹤0.01%	1022
2020 Q3	$4.87M	Sell	43,270 -6,281	-13%	-$625K	0.01%	734
2020 Q2	$4.72M	Sell	49,551 -13,864	-22%	-$1.34M	0.01%	732
2020 Q1	$5.7M	Buy	+63,415	New	+$4.93M	0.02%	596
2019 Q2	–	Sell	-5,646	Closed	-$263K	–	2257
2019 Q1	$263K	Sell	5,646 -88,224	-94%	-$3.87M	﹤0.01%	1526
2018 Q4	$4.09M	Sell	93,870 -95,335	-50%	-$4.76M	0.01%	796
2018 Q3	$10.8M	Buy	189,205 +184,178	+3,664%	+$9.05M	0.03%	549
2018 Q2	$244K	Sell	5,027 -129,866	-96%	-$4.73M	﹤0.01%	1513
2018 Q1	$5.27M	Buy	+134,893	New	+$5.73M	0.02%	608

Other funds holding XLRN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Federated Hermes's XLRN Position: Q2 2021 in Review

Federated Hermes sold out of Acceleron Pharma (XLRN) in Q2 2021, closing a stake of 13,650 shares — an estimated $1.85M sold.

Federated Hermes first reported a position in XLRN in Q1 2018 and held it in 10 quarters. The position peaked at $10.8M in Q3 2018. 271 funds tracked by Wall St. Rank hold XLRN as of Q2 2021.

Federated Hermes reported no remaining Acceleron Pharma position as of Q2 2021 after selling out during the quarter.
Federated Hermes sold 13,650 Acceleron Pharma shares in Q2 2021, an estimated $1.85M.
Federated Hermes first reported a position in Acceleron Pharma in Q1 2018 and held it in 10 quarters.
Federated Hermes's Acceleron Pharma position peaked at $10.8M in Q3 2018.
271 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2021.

Based on Federated Hermes's 13F filing for Q2 2021, filed 16 Aug 2021.